Jeffrey Swanson to Substance-Related Disorders
This is a "connection" page, showing publications Jeffrey Swanson has written about Substance-Related Disorders.
Connection Strength
0.689
-
Bareis N, Edlund M, Ringeisen H, Guyer H, Dixon LB, Olfson M, Smith TE, Chwastiak L, Monroe-DeVita M, Swartz M, Swanson J, Sinclair Hancq E, Geiger P, Kreski NT, Stroup TS. Characterizing Schizophrenia Spectrum Disorders: Results of the U.S. Mental and Substance Use Disorders Prevalence Study. Psychiatr Serv. 2025 Jan 01; 76(1):2-12.
Score: 0.139
-
Easter MM, Swanson JW, Crozier WE, Robertson AG, Garrett BL, Modjadidi K, Swartz MS. North Carolina Specialty Courts, Treatment Access, and the Substance Use Crisis: A Promising but Underfunded Model. Psychiatr Serv. 2021 12 01; 72(12):1471-1474.
Score: 0.111
-
Robertson AG, Swanson JW, Lin H, Easter MM, Frisman LK, Swartz MS. Influence of Criminal Justice Involvement and Psychiatric Diagnoses on Treatment Costs Among Adults With Serious Mental Illness. Psychiatr Serv. 2015 Sep; 66(9):907-9.
Score: 0.073
-
Robertson AG, Swanson JW, Frisman LK, Lin H, Swartz MS. Patterns of justice involvement among adults with schizophrenia and bipolar disorder: key risk factors. Psychiatr Serv. 2014 Jul; 65(7):931-8.
Score: 0.069
-
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophr Res. 2008 Mar; 100(1-3):39-52.
Score: 0.044
-
Swanson J, Van Dorn RA, Swartz MS. Effectiveness of atypical antipsychotics for substance use in schizophrenia patients. Schizophr Res. 2007 Aug; 94(1-3):114-8.
Score: 0.042
-
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M, Miller DD, Reimherr F, Khan A, Ca?ive JM, Lieberman JA. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv. 2006 Aug; 57(8):1110-6.
Score: 0.040
-
Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Stroup TS, McEvoy JP, Lieberman JA. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry. 2006 May; 63(5):490-9.
Score: 0.039
-
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller DD, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, Lieberman JA. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis. 2006 Mar; 194(3):164-72.
Score: 0.038
-
Elbogen EB, Swanson JW, Swartz MS, Van Dorn R. Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability. J Nerv Ment Dis. 2005 Oct; 193(10):673-9.
Score: 0.037
-
Swartz MS, Swanson JW, Hannon MJ. Detection of illicit substance use among persons with schizophrenia by radioimmunoassay of hair. Psychiatr Serv. 2003 Jun; 54(6):891-5.
Score: 0.032
-
Van Dorn RA, Swanson JW, Swartz MS, Elbogen EB. The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia. Ment Health Serv Res. 2005 Jun; 7(2):123-34.
Score: 0.009
-
Rosenberg SD, Swanson JW, Wolford GL, Osher FC, Swartz MS, Essock SM, Butterfield MI, Marsh BJ. The five-site health and risk study of blood-borne infections among persons with severe mental illness. Psychiatr Serv. 2003 Jun; 54(6):827-35.
Score: 0.008
-
Butterfield MI, Bosworth HB, Meador KG, Stechuchak KM, Essock SM, Osher FC, Goodman LA, Swanson JW, Bastian LA, Horner RD. Gender differences in hepatitis C infection and risks among persons with severe mental illness. Psychiatr Serv. 2003 Jun; 54(6):848-53.
Score: 0.008